Bionik Laboratories Showcases InMotion® Robots at Korea’s Largest Medical Device Exhibition

Robotics company, Bionik Laboratories Corp., (OTCPINK: BNKL), displaying its InMotion® Robots at the Korea International Medical and Hospital Equipment Show (KIMES) from March 23 – 26, 2023.

Bionik’s exclusive partner in South Korea is Curexo, a recognized leader in medical device distribution. Bionik received regulatory approval for its InMotion® robotics technology from the South Korean Ministry of Food and Drug Safety in early 2020.


  • Bionik’s InMotion® Robots help patients to regain arm and hand movement following a stroke.
  • Through Curexo, Bionik has installed its devices in South Korea at the Pusan National University’s Yangsan Hospital (PNUYH), Seoul National University Hospital (SNUH), Myongji Choonhye Hospital, and a number of Veterans hospitals.
  • Bionik CEO, Richard Russo, said the company values its long-standing partnership with Curexo, and its strong commitment to bringing advancements in stroke recovery care to the South Korea market.
  • KIMES is Korea’s largest medical device exhibition, with 1,300 companies participating in 2023.

 About Bionik Laboratories

Bionik Laboratories is a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges. The company offers its technology to therapists directly and offers services to patients in its clinical centers. Bionik has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Bionik Laboratories Showcases InMotion® Robots at Korea’s Largest Medical Device Exhibition

Editor Prism MarketView